# Evaluation of the therapeutic effects of smoking cessation on chronic central serous chorioretinopathy

**Authors:** Tatsuo Nagata, Nobuhisa Ochiai, Hiroyuki Kondo, Kazuma Oku, Mizuki Tsurusaki, Takuma Futami, Akihisa Watanabe, Itsuka Matsushita

PMC · DOI: 10.1038/s41598-025-10628-4 · Scientific Reports · 2025-07-24

## TL;DR

This study shows that quitting smoking helps chronic CSCR patients improve more than nonsmokers, making smoking cessation a useful initial treatment.

## Contribution

This is the first study to demonstrate that smoking cessation improves chronic CSCR outcomes in smokers.

## Key findings

- 77.8% of smokers who quit showed improvement without laser treatment, compared to 48.0% of nonsmokers.
- Smoking cessation was associated with a significantly higher improvement rate in chronic CSCR patients.
- Six out of 22 smokers reduced their smoking to one or two cigarettes per day.

## Abstract

Although there have been reports that cigarette smoking is a risk factor for the development of central serous chorioretinopathy (CSCR), there have been no reports that have determined whether smoking cessation is helpful in the resolution of CSCR. The purpose of this study was to evaluate the effects of smoking cessation on chronic CSCR. Fifty-two eyes of 45 patients (22 smokers and 23 nonsmokers) diagnosed with chronic CSCR at our hospital from January 2016 to February 2023 were studied. All patients with CSCR were instructed to take lutein supplements and, if they were smokers, to quit. Among the 52 eyes with chronic CSCR, 33 (63.5%) improved after that instruction, 14 (26.9%) required a laser for CSCR resolution, and 5 (9.6%) had persistent CSCR. Among the 22 smokers who received smoking cessation instructions, 16 stopped smoking, and 6 reduced their smoking to one or two per day. The rate of improvement without laser photocoagulation in chronic CSCR was significantly higher in smokers (77.8%) than in nonsmokers (48.0%) (p = 0.026). The results indicate that chronic CSCR patients who smoke have a higher rate of improvement when they quit smoking than CSCR patients who do not smoke. This study is the first to demonstrate that reducing the risk factor for smoking is a useful initial treatment for CSCR patients who smoke.

The online version contains supplementary material available at 10.1038/s41598-025-10628-4.

## Linked entities

- **Diseases:** central serous chorioretinopathy (MONDO:0018616)

## Full-text entities

- **Diseases:** CSCR (MESH:D056833)
- **Chemicals:** lutein (MESH:D014975)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12290093/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12290093/full.md

## References

1 references — full list in the complete paper: https://tomesphere.com/paper/PMC12290093/full.md

---
Source: https://tomesphere.com/paper/PMC12290093